Target
$119.82 → $119.81
Current stock research snapshot · 7/8/26 49 days old
RVTYRevvity
Investment conviction●●○○○2 of 5 · current snapshot
Research target$119.81Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/8/26
Market cap$12.69BSnapshot value · 7/8/26
Research history
See all RVTY changes ↗What changed
Reagents + proteogenomics pure-play. BioLegend (antibodies/reagents) + TotalSeq (multi-omics) + newborn screening installed base. Recurring reagent pull is the moat.
Multi-omics adoption driving reagent demand; newborn screening franchise expansion; proteogenomics integration tailwind.
Reagent commoditization risk; competitive pressure from larger players (Thermo, Danaher); academic budget sensitivity.
Bullish — Testing upper bound of 3-year stage-1 base with momentum in bullish regime; listed in recent gainers and diagnostics group strength (Aug 21-25). [X search Aug 2026]
Snapshot · 7/8/26🟢 Lean-Bull · ins-$0.2M · 13F 13+/10-×0.5 · short↓0.17
Snapshot · 7/8/26Timestamped research update
Deep research update
653 words · Updated Aug 2, 2026 · 4 sources
Research in development: this latest 653-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Revvity is a life sciences tools and diagnostics company providing reagents, antibodies, instruments, software, and services that span the drug discovery-to-diagnosis workflow. Core assets: BioLegend (antibodies, TotalSeq multi-omics), newborn screening, immunodiagnostics, and informatics software. ~11,000 employees, presence in 160+ countries, S&P 500 component.
FY2025 revenue $2,856M (+3.7% YoY); gross margin 54.8%; operating margin 12.5%; net margin 8.4%. Q1 2026 revenue $711.1M (+7.0% YoY). Life Sciences ~58% of revenue (reagents, BioLegend, software); Diagnostics ~42% (immunodiagnostics, reproductive health, newborn screening). Goodwill $6.61B = 232% of FY2025 revenue — highly acquisitive model. (Source: FY2025 10-K filed 2026-02-24; Q1 2026 10-Q filed 2026-05-12)
BioLegend's antibody catalog + TotalSeq multi-omics platform creates protocol-level lock-in for researchers. Once a lab builds workflows around specific antibody clones, switching invalidates prior experimental data and requires 3-18 months of re-validation. This consumables-based recurring revenue model is the Picks & Shovels thesis applied to healthspan research infrastructure.
- BioLegend acquired Sep 2021 for $5.25B — now the growth engine within Life Sciences; TotalSeq oligo-conjugated antibodies enable CITE-seq single-cell proteogenomic workflows that combine protein + RNA readouts
- Switching cost model: academic lab reagent spend $50K-200K/yr; antibody change requires 3-6 months re-validation → estimated $25K-100K switching cost per lab; pharma clinical assay re-validation = $500K-$2M and 12-18 months
- Q1 2026 revenue $711.1M (+7.0% YoY) shows modest acceleration from FY2025's +3.7%; Life Sciences +2% organic, Diagnostics +5% organic in FY2025
- China Immunodiagnostics divestiture announced Apr 2026: letter of intent for up to $200M sale — removes China regulatory exposure but also removes a growth option in the largest diagnostics market
- R&D spend $215.8M (7.6% of revenue) in FY2025 — reasonable for tools but not exceptional; most innovation comes through M&A, not internal R&D
Protocol-level antibody lock-in — researchers standardize on specific BioLegend clone IDs (e.g., anti-CD3 clone UCHT1, anti-CD4 clone RPA-T4). Changing suppliers means re-validating every antibody in a multi-color flow cytometry panel (6-18 months for clinical assays). TotalSeq extends this to single-cell multi-omics, where the antibody-oligo conjugate is proprietary. The moat is real but narrow: it's consumable-level stickiness, not an infrastructure monopoly. Clone IDs are not patent-protected — competing suppliers can (and do) develop their own clones against the same targets.
- Acquisition-driven strategy: $6.61B goodwill on $2.86B revenue means the balance sheet quality is poor; M&A integration risk is existential
- Low organic growth (2-5%): thesis depends on deploying capital for acquisitions that actually create value — most life sciences tools M&A destroys value
- Thermo Fisher / Danaher scale: these consolidators can outspend 10-15x on R&D, manufacturing, and distribution; RVTY fights niche battles
- China IDX divestiture: removes ~$200M in assets but loses China diagnostics presence; tariffs on China-sourced manufacturing inputs remain
- FX exposure: majority of revenue outside US; a strong dollar is a persistent headwind
- SG&A bloat: 34.7% of revenue on SG&A vs. 7.6% on R&D — the company spends 4.6x more on selling/admin than on innovation
- What is BioLegend's standalone revenue and growth rate? (not separately disclosed after 2021 acquisition)
- What is the TotalSeq revenue contribution vs. traditional antibody catalog revenue?
- Can organic growth accelerate above 5% without M&A, or is RVTY structurally a low-growth compounder?
- When does the China IDX sale close, and how is the $200M deployed — debt reduction or new M&A?
NEEDS_MORE_DATA — the antibody consumables moat is real but narrow, and the switching cost model shows only moderate stickiness (50-100% of annual spend at academic level, lower at pharma scale). The acquisition-driven growth model with $6.61B goodwill is not a high-quality compounding thesis. Toll-road score: STRONG PROXY (6/10) — sells picks and shovels to healthspan researchers but does not control an irreplaceable bottleneck.
Primary and supporting material
Sources
4 sources preserved from the latest qualified research update.